Form D · Pharmaceuticals
Tioma Therapeutics, Inc.
Brisbane, CA · CIK 0001630680
Offering snapshot reported Aug 17, 2016 · SEC filing
- Reported sold
- $33.2M Offering amount: $86.3M
- Investors reported
- 12 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jun 25, 2015 As reported in this filing
Fundraising history
Reported soldDates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.
What changed?
Latest filing versus its linked predecessor, where available.
- Reported sold$8,134,451 → $33,176,948
- Reported investors10 → 12
- Minimum accepted$50,000 → $0
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Aug 17, 2016 | Amendment | $33,176,948 | $25,042,497vs Aug 7, 2015 | 12 | SEC filing |
| Aug 7, 2015 | Initial | $8,134,451 | No comparison | 10 | SEC filing |
| Feb 12, 2015 | Initial | $1,269,350 | No comparison | 3 | SEC filing |
Offering details
- Securities
- Equity, Other
- Exemptions
- 06b
- Duration over one year
- Yes
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-245292
Issuance and sale of shares of Series A Preferred Stock and the underlying shares of Common Stock issuable upon conversion thereof.
Source: Form D, filed Aug 17, 2016. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Kalthleen L. Beckmann | Executive |
| Kathleen L. Beckmann | Executive |
| Charles Bolten | Director |
| Dan Broderick | Director |
| George Capps | Executive |
| Jill Carroll | Director |
| John Donovan | Director, Executive |
| William Frazier | Director |
| Robert W. Karr | Executive |
| Pamela T. Manning | Executive |
| John Mc Kearn | Director |
| Peter Moldt | Director |
| Carole L. Nuechterlein | Director |
| Bobby W. Sandage, Jr. | Director |
| James Stutz | Executive |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
2000 Sierra Point Parkway, Suite 700
Brisbane, CA, 94005
Brisbane, CA, 94005